Literature DB >> 9279670

Postoperative inflammatory response to phacoemulsification and extracapsular cataract surgery: aqueous flare and cells.

M V Pande1, D J Spalton, M G Kerr-Muir, J Marshall.   

Abstract

PURPOSE: To compare the postoperative blood-aqueous barrier (BAB) breakdown induced by phacoemulsification with continuous curvilinear capsulorhexis (CCC) and by extracapsular cataract extraction (ECCE) with a linear capsulotomy.
SETTING: Cataract and Refractive Surgery Research Unit, Department of Ophthalmology, St. Thomas' Hospital, London, United Kingdom.
METHODS: Anterior chamber flare and cells were measured preoperatively and 1 day, 1 week, and 1 and 3 months postoperatively in two parallel groups of 31 consecutive cataractous eyes. In Group 1, one surgeon performed ECCE with a linear capsulotomy; in Group 2, a second surgeon performed divide and conquer phacoemulsification with CCC. The preoperative, intraoperative, and postoperative medication regimen was the same in both groups.
RESULTS: Group 2 eyes had significantly lower anterior chamber flare and cell measurements in the first postoperative month than Group 1 eyes (.01 < P < .00001).
CONCLUSIONS: Phacoemulsification with CCC induced a less severe BAB breakdown than ECCE with a linear capsulotomy. Phacoemulsification with CCC may be preferable in high-risk eyes such as those with glaucoma, diabetes, or uveitis, which are prone to complications resulting from postoperative BAB breakdown.

Entities:  

Mesh:

Year:  1996        PMID: 9279670     DOI: 10.1016/s0886-3350(96)80160-x

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  19 in total

Review 1.  [New methods for the prevention of posterior capsule opacification].

Authors:  G U Auffarth; T M Rabsilber; A J Reuland
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

2.  Outcome of phacoemulsification in patients with uveitis.

Authors:  M A Elgohary; P J McCluskey; H M A Towler; N Okhravi; R P Singh; R Obikpo; S S Lightman
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

3.  A 1-year study on carbon, titanium surface-modified intraocular lens in rabbit eyes.

Authors:  Zhaoxu Yuan; Huimin Sun; Jiaqin Yuan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-10       Impact factor: 3.117

4.  Evaluation of Posterior Capsular Opacification following Phacoemulsification, Extracapsular and Small Incision Cataract Surgery.

Authors:  P S Moulick; Fea Rodrigues; K Shyamsundar
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Neovascular glaucoma following Nd:YAG laser capsulotomy in a patient with diabetes and syphilitic uveitis.

Authors:  Hong-Zin Lin; Yuan-Chieh Lee
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2015-09-05

6.  Phacoemulsification versus extracapsular cataract extraction: a comparative study of cell survival and growth on the human capsular bag in vitro.

Authors:  M Quinlan; I M Wormstone; G Duncan; P D Davies
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

7.  Combined cataract and glaucoma surgery: the effect of pupil enlargement on surgical outcomes (an American Ophthalmological Society thesis).

Authors:  L Jay Katz; Camila Zangalli; Raymond Clifford; Benjamin Leiby
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

8.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

9.  Hydrophobic acrylic versus heparin surface-modified polymethylmethacrylate intraocular lens: a biocompatibility study.

Authors:  Daniele Tognetto; Lisa Toto; Daniela Minutola; Enzo Ballone; Marta Di Nicola; Rocco Di Mascio; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-17       Impact factor: 3.117

10.  Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery.

Authors:  C-G Laurell; C Zetterström
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.